Schizophrenia Clinical Trials in West Palm Beach, Florida

8 studies are recruiting for schizophrenia in West Palm Beach, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Local Institution - 0044, West Palm Beach, Florida
    Locations
    59 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07686263 on ClinicalTrials.gov

  2. 52-week Open Label Safety-Tolerability Study

    Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Health Synergy Clinical Research, West Palm Beach, Florida
    Locations
    23 in total
    Run by
    LB Pharmaceuticals Inc.

    See if you can join NCT07369154 on ClinicalTrials.gov

  3. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Clinical Site, West Palm Beach, Florida
    Locations
    42 in total
    Run by
    MapLight Therapeutics

    See if you can join NCT07459647 on ClinicalTrials.gov

  4. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Health Synergy Clinical Research, West Palm Beach, Florida
    Locations
    64 in total
    Run by
    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

  5. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

    Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Health Synergy Clinical Research LLC Site, West Palm Beach, Florida
    Locations
    73 in total
    Run by
    Otsuka Pharmaceutical Development & Commercialization, Inc.

    See if you can join NCT06894212 on ClinicalTrials.gov

  6. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, West Palm Beach, Florida
    Locations
    57 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

  7. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, West Palm Beach, Florida
    Locations
    20 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

  8. A Study to Evaluate the Effect of KarXT on Urological Safety

    The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

    Stage
    Phase 4
    Ages
    18 to 65
    Site
    Health Synergy Clinical Research, West Palm Beach, Florida
    Locations
    13 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07221877 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.